UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N‑Acylethanolamine Acid Amidase Inhibitors

Journal of medicinal chemistry, 2017-01, Vol.60 (1), p.4-46

2017

Volltextzugriff (PDF)

Novel PD-L1-Targeted Phenyl-Pyrazolone Derivatives with Antioxidant Properties

Molecules (Basel, Switzerland), 2023-04, Vol.28 (8), p.3491

2023

Volltextzugriff (PDF)

Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents

Molecules (Basel, Switzerland), 2022-05, Vol.27 (10), p.3316

2022

Volltextzugriff (PDF)

Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target

Journal of medicinal chemistry, 2023-11, Vol.66 (21), p.14391-14410

2023

Volltextzugriff (PDF)

4-Anilinoquinazoline Derivatives as the First Potent NOD1-RIPK2 Signaling Pathway Inhibitors at the Nanomolar Range

Journal of medicinal chemistry, 2024-10

2024

Volltextzugriff (PDF)

New Potent RIPK2 Inhibitors as a Promising Therapeutic Avenue for Colitis Through the Blockade of NOD Inflammatory Pathways

Journal of medicinal chemistry, 2024-10, Vol.67 (19), p.17407-17428

2024

Volltextzugriff (PDF)

Synthesis and biological evaluation of ferrocene-based cannabinoid receptor 2 ligands

Future medicinal chemistry, 2018-03, Vol.10 (6), p.631-638

2018

Volltextzugriff (PDF)

Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction

European journal of medicinal chemistry, 2022-06, Vol.236, p.114343-114343, Article 114343

2022

Volltextzugriff (PDF)

Abstract 5340: Novel small-molecule antagonists of the PD1/PD-L1 axis

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5340-5340

2020

Volltextzugriff (PDF)

Benzo[d]thiazol-2(3H)-ones as new potent selective CB 2 agonists with anti-inflammatory properties

European journal of medicinal chemistry, 2019-03, Vol.165, p.347

2019

Volltextzugriff (PDF)

Towards New Anti-inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP-BIR2

ChemMedChem, 2024-10, p.e202400567

2024

Volltextzugriff (PDF)

Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules

Journal of hepatology, 2019-06, Vol.70 (6), p.1159-1169

2019

Volltextzugriff (PDF)

Benzo[d]thiazol-2(3H)-ones as new potent selective CB2 agonists with anti-inflammatory properties

European journal of medicinal chemistry, 2019-03, Vol.165, p.347-362

2019

Volltextzugriff (PDF)

One- or Two-Step Synthesis of C‑8 and N‑9 Substituted Purines

Journal of organic chemistry, 2018-01, Vol.83 (1), p.422-430

2018

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of potent FAAH inhibitors

Bioorganic & medicinal chemistry letters, 2016-06, Vol.26 (11), p.2701-2705

2016

Volltextzugriff (PDF)

Development of novel oxazolo[5,4-d]pyrimidines as competitive CB2 neutral antagonists based on scaffold hopping

European journal of medicinal chemistry, 2018-02, Vol.146, p.68-78

2018

Volltextzugriff (PDF)

ChemInform Abstract: A Rapid Route for the Preparation of Pyrimido[5,4-d]- and Pyrido[3,2-d]oxazoles

ChemInform, 2015-08, Vol.46 (34), p.no-no

2015

Volltextzugriff (PDF)

A rapid route for the preparation of pyrimido[5,4-d]- and pyrido[3,2-d]oxazoles

Tetrahedron letters, 2015-05, Vol.56 (19), p.2448-2450

2015

Volltextzugriff (PDF)

Synthesis of Bioorganometallic Nanomolar-Potent CB 2 Agonists Containing a Ferrocene Unit

Organometallics, 2016-10, Vol.35 (19), p.3361-3368

2016

Volltextzugriff (PDF)

Synthesis of Bioorganometallic Nanomolar-Potent CB2 Agonists Containing a Ferrocene Unit

Organometallics, 2016-10, Vol.35 (19), p.3361-3368

2016

Volltextzugriff (PDF)

3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis

Bioorganic & medicinal chemistry, 2013-09, Vol.21 (17), p.5383-5394

2013

Volltextzugriff (PDF)

Switching cannabinoid response from CB2 agonists to FAAH inhibitors

Bioorganic & medicinal chemistry letters, 2014-03, Vol.24 (5), p.1322-1326

2014

Volltextzugriff (PDF)

Therapeutical Potential of CB 2 Receptors in Immune-Related Diseases

Current molecular pharmacology, 2014-04, Vol.6 (3), p.183-203

2014

Volltextzugriff (PDF)

Du cannabis aux agonistes sélectifs du récepteur CB 2: Des molécules aux nombreuses vertus thérapeutiques

M.S. Médecine sciences, 2013-05, Vol.29 (5), p.523-528

2013

Volltextzugriff (PDF)

Development of novel oxazolo[5,4-d]pyrimidines as competitive CB 2 neutral antagonists based on scaffold hopping

European journal of medicinal chemistry, 2018-02, Vol.146, p.68

2018

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(28)

Sprache

Englisch
(26)
Französisch
(2)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N‑Acylethanolamine Acid Amidase Inhibitors

Novel PD-L1-Targeted Phenyl-Pyrazolone Derivatives with Antioxidant Properties

Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents

Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target

4-Anilinoquinazoline Derivatives as the First Potent NOD1-RIPK2 Signaling Pathway Inhibitors at the Nanomolar Range

New Potent RIPK2 Inhibitors as a Promising Therapeutic Avenue for Colitis Through the Blockade of NOD Inflammatory Pathways

Synthesis and biological evaluation of ferrocene-based cannabinoid receptor 2 ligands

Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction

Abstract 5340: Novel small-molecule antagonists of the PD1/PD-L1 axis

Benzo[d]thiazol-2(3H)-ones as new potent selective CB 2 agonists with anti-inflammatory properties

Towards New Anti-inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP-BIR2

Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules

Benzo[d]thiazol-2(3H)-ones as new potent selective CB2 agonists with anti-inflammatory properties

One- or Two-Step Synthesis of C‑8 and N‑9 Substituted Purines

Design, synthesis and biological evaluation of potent FAAH inhibitors

Development of novel oxazolo[5,4-d]pyrimidines as competitive CB2 neutral antagonists based on scaffold hopping

ChemInform Abstract: A Rapid Route for the Preparation of Pyrimido[5,4-d]- and Pyrido[3,2-d]oxazoles

A rapid route for the preparation of pyrimido[5,4-d]- and pyrido[3,2-d]oxazoles

Synthesis of Bioorganometallic Nanomolar-Potent CB 2 Agonists Containing a Ferrocene Unit

Synthesis of Bioorganometallic Nanomolar-Potent CB2 Agonists Containing a Ferrocene Unit

3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis

Switching cannabinoid response from CB2 agonists to FAAH inhibitors

Therapeutical Potential of CB 2 Receptors in Immune-Related Diseases

Du cannabis aux agonistes sélectifs du récepteur CB 2: Des molécules aux nombreuses vertus thérapeutiques

Development of novel oxazolo[5,4-d]pyrimidines as competitive CB 2 neutral antagonists based on scaffold hopping

Suchergebnisse filtern